SPRC.US Scisparc Ltd

Healthcare Biotechnology USA Stocks
0.3290 USD
Close of Nov 17, 2026
0.3071 29.88
Market cap
USD 810K
P/E
0.0x
P/B
0.22x
ROE
-416.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is SPRC.US undervalued?

Graham number

The Graham number of Scisparc Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scisparc Ltd fundamental analysis

No fundamental analysis for Scisparc Ltd yet.

Scisparc Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scisparc Ltd

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop…

Full company profile